Abstract: The present inventors successfully produced monoclonal antibodies that are specific to only soluble A? oligomers, but do not recognize soluble A? monomers, which are physiological molecules. It was demonstrated that the antibodies are useful as diagnostic/therapeutic monoclonal antibodies for Alzheimer's disease.
Type:
Application
Filed:
February 9, 2012
Publication date:
June 7, 2012
Applicants:
National Center for Geriatrics and Gerontology, Immunas Pharma, Inc.
Abstract: The present inventors successfully produced monoclonal antibodies that are specific to only soluble A? oligomers, but do not recognize soluble A? monomers, which are physiological molecules. It was demonstrated that the antibodies are useful as diagnostic/therapeutic monoclonal antibodies for Alzheimer's disease.
Type:
Application
Filed:
August 5, 2010
Publication date:
April 28, 2011
Applicants:
Immunas Pharma, Inc., National Center for Geriatrics and Gerontology
Abstract: The present inventors successfully produced monoclonal antibodies that are specific to only soluble A? oligomers, but do not recognize soluble A? monomers, which are physiological molecules. It was demonstrated that the antibodies are useful as diagnostic/therapeutic monoclonal antibodies for Alzheimer's disease.
Type:
Application
Filed:
July 31, 2009
Publication date:
November 18, 2010
Applicants:
Immunas Pharma, Inc., National Center for Geriatrics and Gerontology
Abstract: Disclosed is an antibody having a high inhibitory effect on amyloid fibril formation. An antibody is produced by using a liposome containing a GM1 ganglioside at a predetermined ratio as an immunogen. Thus, the sequences of four types of antibodies each having a high inhibitory effect on amyloid fibril formation can be provided.
Type:
Application
Filed:
April 22, 2010
Publication date:
October 21, 2010
Applicants:
MEDICAL & BIOLOGICAL LABORATORIES CO., LTD., THE PRESIDENT OF NATIONAL CENTER FOR GERIATRICS AND GERONTOLOGY, KATSUHIKO YANAGISAWA
Abstract: The present inventors successfully produced monoclonal antibodies that are specific to only soluble A? oligomers, but do not recognize soluble A? monomers, which are physiological molecules. It was demonstrated that the antibodies are useful as diagnostic/therapeutic monoclonal antibodies for Alzheimer's disease.
Type:
Application
Filed:
April 19, 2010
Publication date:
October 14, 2010
Applicants:
Immunas Pharma, Inc., National Center for Geriatrics and Gerontology
Abstract: Disclosed is an antibody having a high inhibitory effect on amyloid fibril formation. An antibody is produced by using a liposome containing a GM1 ganglioside at a predetermined ratio as an immunogen. Thus, the sequences of four types of antibodies each having a high inhibitory effect on amyloid fibril formation can be provided.
Type:
Grant
Filed:
June 19, 2006
Date of Patent:
June 22, 2010
Assignees:
Medical & Biological Laboratories Co., Ltd., The President of National Center for Geriatrics and Gerontology
Abstract: A method for screening therapeutic agents for disuse muscular atrophy is provided that includes the steps of interacting a selected protein with a polyubiquitin chain in the presence of a candidate therapeutic agent, and determining the effect of the candidate on the binding strength between the protein and the polyubiquitin chain. The effect may be observed by color development on a substrate when the steps are carried out by way of an enzyme-linked immunosorbent assay, or by direct observation via NMR spectroscopy, X-ray crystal analysis, electron microscopy or surface plasmon resonance.
Type:
Grant
Filed:
December 7, 2004
Date of Patent:
April 20, 2010
Assignees:
National Institute of Advanced Industrial Science and Technology, National Center for Geriatrics and Gerontology
Abstract: The present inventors successfully produced monoclonal antibodies that are specific to only soluble A? oligomers, but do not recognize soluble A? monomers, which are physiological molecules. It was demonstrated that the antibodies are useful as diagnostic/therapeutic monoclonal antibodies for Alzheimer's disease.
Type:
Application
Filed:
July 31, 2009
Publication date:
February 4, 2010
Applicants:
Immunas Pharma, Inc., Japan as Represented by President of National Center for Geriatrics and Gerontology
Abstract: An objective of the present invention is to provide a safe and effective vaccine therapy for Alzheimer's disease. A minus strand RNA viral vector carrying amyloid gene was constructed, and administered intranasally to 24- to 25-months-old APP transgenic mice. The level of serum anti-A 42 antibody was determined and showed to be markedly higher than the control. The results of histological investigation showed that the administration of a vector of the present invention markedly reduced senile plaques in all of the frontal lobe, parietal lobe, and hippocampus. The brain A level was also markedly reduced. Furthermore, the administration of a vector of the present invention did not result in lymphocyte infiltration in the central nervous system.
Type:
Application
Filed:
April 20, 2006
Publication date:
July 2, 2009
Applicants:
JAPAN AS REPRESENTED BY PRESIDENT OF NATIONAL CENTER FOR GERIATRICS AND GERONTOLOGY, DNAVEC CORPORATION
Abstract: Disclosed is an antibody having a high inhibitor effect on amyloid fibril formation. An antibody is produced by using a liposome containing a GM1 ganglioside at a predetermined ratio as an immunogen. Thus, the sequences of four types of antibodies each having a high inhibitory effect on amyloid fibril formation can be provided.
Type:
Application
Filed:
June 19, 2006
Publication date:
April 30, 2009
Applicants:
Medical & Biological Laboratories Co., Ltd., The President of National Center for Geriatrics and Gerontology, Katsuhiko Yanagisawa c/o National Center for Geriatrics and Gerontology
Abstract: [Problem] Providing a novel interaction between proteins. [Solution Means] It has been found that there is an interaction between proteins between proteasome and ZNF216 (or AWP1). It has also been found that there is an interaction between proteins between a polyubiquitin chain and ZNF216 (or AWP1). By utilizing this novel interaction between the proteins, a therapeutic agent for disuse muscular atrophy, and a method for screening the therapeutic agents for disuse muscular atrophy, a marker for disease diagnosis, a method for evaluating the risk of onset of the disuse muscular atrophy, etc., are provided.
Type:
Application
Filed:
December 7, 2004
Publication date:
September 18, 2008
Applicants:
National Institute of Advanced Industrial Science and Technology, National Center for Geriatrics and Gerontology